Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 21, Issue 5, 2015, Pages 1176-1186

  Feuerstein, Joseph D ^a   Cullen, Garret ^a,b   Cheifetz, Adam S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

adalimumab; anti tumor necrosis factor; autoimmune disease; certolizumab pegol; complications; demyelinating diseases; golimumab; infliximab; infusion reactions; psoriasis

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; HISTONE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ANTIBODY PRODUCTION; ANTIGENICITY; AUTOIMMUNE DISEASE; CUTANEOUS LEUKOCYTOCLASTIC VASCULITIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ECZEMA; HUMAN; IMMUNITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; LEUKOCYTOCLASTIC VASCULITIS; LUPUS LIKE SYNDROME; META ANALYSIS (TOPIC); MONOTHERAPY; NONHUMAN; PATHOGENESIS; PREMEDICATION; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; REVIEW; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PROGNOSIS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; PROGNOSIS; TUMOR NECROSIS FACTORS;

EID: 84929092318     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000279     Document Type: Review

References (91)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
2. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
3. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
4. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
5. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. New Engl J Med. 2007;357:228-238.
6. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. New Engl J Med. 2007;357: 239-250.
7. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
8. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-To-severe ulcerative colitis. Gastroenterology. 2012;142:257-265. e3.
9. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-Tosevere ulcerative colitis. Gastroenterology. 2014;146:85-95; quiz e14-e5.
10. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-To-severe ulcerative colitis. Gastroenterology. 2014;146:96-109. e1.
11. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-Term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
12. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
13. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
14. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
15. Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. New Engl J Med. 2013;369:754-762.
16. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-924.
17. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis. 2009;15:1264-1275.
18. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-Analysis. Am J Gastroenterol. 2013;108: 40-47; quiz 48.
19. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2011;60:41-48.
20. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
21. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
22. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-Alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944-948.
23. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-Analysis. Eur J Gastroenterol Hepatol. 2012;24: 1078-1085.
24. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-3497.
25. O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-Analysis. Inflamm Bowel Dis. 2014;20:1-6.
26. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
27. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:51-58.
28. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
29. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392-400. e3.
30. Fidder H, Schnitzler F, Ferrante M, et al. Long-Term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501-508.
31. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
32. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315-1324.
33. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
34. Duburque C, Lelong J, Iacob R, et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther. 2006;24:851-858.
35. Vermeire S, Van Assche G, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol. 2009;23:101-112.
36. Wasserman MJ, Weber DA, Guthrie JA, et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004;31:1912-1917.
37. Lequerre T, Vittecoq O, Klemmer N, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol. 2006;33:1307-1314.
38. Uthman I, Touma Z, El-Sayyad J, et al. Successful retreatment with infliximab in patients with prior severe infusion reactions. Clin Rheumatol. 2006;25:540-541.
39. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 2005;11:442-446.
40. Lee TW, Singh R, Fedorak RN. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther. 2011;34:181-187.
41. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-Tumour necrosis factor-Alpha antibodies. Scand J Gastroenterol. 2009;44:774-781.
42. Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133-1139.
43. Velayos FS, Kahn JG, Sandborn WJ, et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol. 2013;11:654-666.
44. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20:1996-2003.
45. Fiorino G, Danese S, Pariente B, et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-A agents. Autoimmun Rev. 2014;13:15-19.
46. Katsanos KH, Voulgari PV, Tsianos EV. Inflammatory bowel disease and lupus: a systematic review of the literature. J Crohns Colitis. 2012; 6:735-742.
47. Pisetsky DS. Tumor necrosis factor a blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum. 2000;43:2381-2382.
48. Atzeni F, Ardizzone S, Sarzi-Puttini P, et al. Autoantibody profile during short-Term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther. 2005;22:453-461.
49. Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev. 2013;12:703-708.
50. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-Tumor necrosis factor a treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125:32-39.
51. Beigel F, Schnitzler F, Paul Laubender R, et al. Formation of antinuclear and double strand DNA antibodies and frequency of lupus like syndrome in anti TNF a antibody treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:91-98.
52. Benucci M, Saviola G, Baiardi P, et al. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFa blocking agents in rheumatoid arthritis. Clin Rheumatol. 2008;27:91-95.
53. Jansen Biotech Inc. Janssen Simponi Perscribing Information. Available at: https://www.simponi.com/prescribing-information.pdf. Accessed February 25, 2014.
54. Jonsdottir T, Forslid J, van Vollenhoven A, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis. 2004;63:1075-1078.
55. Sellam J, Allanore Y, Batteux F, et al. Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate. Joint Bone Spine. 2005;72:48-52.
56. Araujo-Fernendez S, Ahijon-Lana M, Isenberg D. Drug-induced lupus: including anti-Tumour necrosis factor and interferon induced. Lupus. 2014;23:545-553.
57. Ramos-Casals M, Brito-Zeron P, Soto MJ, et al. Autoimmune diseases induced by TNF-Targeted therapies. Best Pract Res Clin Rheumatol. 2008; 22:847-861.
58. Wilkerson E, Hazey MA, Bahrami S, et al. Golimumab-exacerbated subacute cutaneous lupus erythematosus. Arch Dermatol. 2012;148:1186-1190.
59. De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus erythematosus induced by anti-Tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545.
60. Schiff MH, Burmester GR, Kent J, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889-894.
61. Yanai H, Shuster D, Calabrese E, et al. The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies. Inflamm Bowel Dis. 2013;19:2778-2786.
62. Subramanian S, Yajnik V, Sands BE, et al. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis. 2011;17:99-104.
63. Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-Tumor necrosis factor a therapy in 14 patients during an 8-year period at Mayo clinic. Mayo Clin Proc. 2009;84:979-984.
64. Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15:757-761.
65. Ramos-Casals M, Diaz-Lagares C, Cuadrado MJ, et al. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev. 2010;9:188-193.
66. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-Targeted therapies: analysis of 233 cases. Medicine. 2007;86:242-251.
67. Verma HD, Scherl EJ, Jacob VE, et al. Anti nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab. J Digest Dis. 2011;12:379-383.
68. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFa antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73:710-713.
69. Sokumbi O, Wetter DA, Makol A, et al. Vasculitis associated with tumor necrosis factor-A inhibitors. Mayo Clinic Proc. 2012;87:739-745.
70. Moustou AE, Matekovits A, Dessinioti C, et al. Cutaneous side effects of anti-Tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol. 2009;61:486-504.
71. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-Alpha blocking agents. J Rheumatol. 2004;31:1955-1958.
72. Perez-Alvarez R, Perez-de-Lis M, Ramos-Casals M. Biologics-induced autoimmune diseases. Curr Opinion Rheumatol. 2013;25:56-64.
73. Desai SB, Furst DE. Problems encountered during anti-Tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-790.
74. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827-836.
75. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat. 2009;20:100-108.
76. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-Tumour necrosis factor a therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheumatic Dis. 2009;68:209-215.
77. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-Tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-1055.
78. Kip KE, Swoger JM, Grandinetti LM, et al. Tumor necrosis factor [alpha] antagonist-Associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. Inflamm Bowel Dis. 2013;19: 1164-1172.
79. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40:233-240.
80. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-A inhibitorinduced psoriasis or psoriasiform exanthemata. Am J Clin Dermatol. 2008;9:1-14.
81. Denadai R, Teixeira FV, Steinwurz F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-A therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7:517-524.
82. Cullen G, Kroshinsky D, Cheifetz A, et al. Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318-1327.
83. Steinwurz F, Denadai R, Saad-Hossne R, et al. Infliximab-induced psoriasis during therapy for Crohn's disease. J Crohns Colitis. 2012;6:610-616.
84. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Care Res. 2008;59:996-1001.
85. Mocci G, Marzo M, Papa A, et al. Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. J Crohns Colitis. 2013;7:769-779.
86. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496-503.
87. Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut. 2009;58:1033-1039.
88. Sfikakis P, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-Tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513-2518.
89. Fiorino G, Allez M, Malesci A, et al. Review article: anti TNF-A induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2009;29:921-927.
90. Flendrie M, Vissers W, Creemers M, et al. Dermatological conditions during TNF-Alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666-R676.
91. Vestergaard C, Deleuran M, Kragballe K. Two cases of atopic dermatitislike conditions induced in psoriasis patients treated with infliximab. J Eur Acad Dermatol Venereol. 2007;21:1272-1274.